OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, October 04, 2016

journal search "talc" - (AACR) Cancer Epidemiology, Biomarkers & Prevention



Search Results | Cancer Epidemiology, Biomarkers & Prevention

34 Results
for term "talc"
by: most recent first
  • Research Articles
    Association between Body Powder Use and Ovarian Cancer: The African American Cancer Epidemiology Study (AACES)
    Joellen M. Schildkraut, Sarah E. Abbott, Anthony J. Alberg, Elisa V. Bandera, Jill S. Barnholtz-Sloan, Melissa L. Bondy, Michele L. Cote, Ellen Funkhouser, Lauren C. Peres, Edward S. Peters, Ann G. Schwartz, Paul Terry, Sydnee Crankshaw, Fabian Camacho, Frances Wang and Patricia G. Moorman

    ...commentary by Trabert, p. 1369 Introduction Genital powder use may be a modifiable risk factor for epithelial ovarian cancer (EOC), the most deadly of all gynecologic cancers (1). In 2010, the International Agency for Research on Cancer (IARC) classified perineal (genital) use of nonasbestos–containing, talc ~~~
  • Commentary
    Body Powder and Ovarian Cancer Risk—What Is the Role of Recall Bias?
    Britton Trabert

    ..., specifically perineal talc use, has been suggested as another potential proinflammatory exposure that may be related to ovarian cancer risk. Several case–control studies have shown an association between genital powder use and increased risk of ovarian cancer (6–9). The International Agency for Research ~~~
  • Research Article
    Is pelvic inflammatory disease a risk factor for ovarian cancer?
    Christina B. Rasmussen, Allan Jensen, Vanna Albieri, Klaus K Andersen and Susanne K. Kjaer

    ...risk factors for ovarian cancer, including endometriosis, talc use and pelvic inflammatory disease (PID), may act through a common inflammatory mechanism. In addition, studies have shown that tubal ligation and hysterectomy protects against ovarian cancer (3) and this protective effect may also ~~~
  • Research Articles
    Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium
    Rikki Cannioto, Michael J. LaMonte, Harvey A. Risch, Chi-Chen Hong, Lara E. Sucheston-Campbell, Kevin H. Eng, J. Brian Szender, Jenny Chang-Claude, Barbara Schmalfeldt, Ruediger Klapdor, Emily Gower, Albina N. Minlikeeva, Gary R. Zirpoli, Elisa V. Bandera, Andrew Berchuck, Daniel Cramer, Jennifer A. Doherty, Robert P. Edwards, Brooke L. Fridley, Ellen L. Goode, Marc T. Goodman, Estrid Hogdall, Satoyo Hosono, Allan Jensen, Susan Jordan, on behalf of The Australian Ovarian Cancer Study Group, Susanne K. Kjaer, Keitaro Matsuo, Roberta B. Ness, Catherine M. Olsen, Sara H. Olson, Celeste Leigh Pearce, Malcolm C. Pike, Mary Anne Rossing, Elizabeth A. Szamreta, Pamela J. Thompson, Chiu-Chen Tseng, Robert A. Vierkant, Penelope M. Webb, Nicolas Wentzensen, Kristine G. Wicklund, Stacey J. Winham, Anna H. Wu, Francesmary Modugno, Joellen M. Schildkraut, Kathryn L. Terry, Linda E. Kelemen and Kirsten B. Moysich

    ..., former), education (less than high school, high school, some college, college graduate, graduate school), talc or genital powder use (no use, genital use, nongenital use), NSAIDs use ( once/week,......(click link above for all 34 articles per search "talc"

Body Powder and Ovarian Cancer Risk—What Is the Role of Recall Bias? (AACR)



(partial view) Cancer Epidemiology, Biomarkers

Serious drug side effects are massively underreported in medical papers



link to paper/media

An astonishing 64 per cent of drug or medical device side effects are left out of the published reports that clinicians so frequently base decisions on. This is the finding of a recent paper published in the journal PLOS Medicine by a team of UK researchers.

Opportunistic Salpingectomy: Benefits Do Not Outweigh Risks: The National Catholic Bioethics Quarterly



(partial view) The National Catholic Bioethics Quarterly (Philosophy Documentation Center)


 

10 Steps to ‘End Cancer As We Know It’ - Blue Ribbon Panel's 10 Recommendations (U.S.)



Oncology Times
 

Blue Ribbon Panel's 10 Recommendations

1. Engage patients to contribute their comprehensive tumor profile data to expand knowledge about what therapies work, in whom, and in which types of cancer. This recommendation would create a privacy-protected new national network in which patients could “pre-register” for clinical trials.
2. Establish a cancer immunotherapy clinical trials network devoted exclusively to discovering and evaluating immunotherapy approaches in oncology. This network could help to speed the development of new cancer vaccines.
3. Identify therapeutic targets to overcome drug resistance through studies that determine the mechanisms that lead cancer cells to become resistant to previously effective treatments.
4. Create a national ecosystem for sharing and analyzing cancer data so that researchers, clinicians, and patients will be able to contribute data, which will facilitate efficient data analysis. This ecosystem would link many of the largest U.S. data repositories.
5. Improve our understanding of fusion oncoproteins (so-called rogue proteins) in pediatric cancer and use new preclinical models to develop inhibitors that target them.
6. Accelerate the development of guidelines for routing monitoring and management of patient-reported symptoms to minimize debilitating side effects of cancer and its treatment.
7. Reduce cancer risk and cancer health disparities through approaches in development, testing and broad adoption of proven prevention strategies. These include tobacco control, colorectal cancer screening and HPV vaccination.
8. Predict response to standard treatments through retrospective analysis of patient specimens.
9. Create dynamic 3D maps of human tumor evolution to document the genetic lesions and cellular interactions of each tumor as it evolves from a precancerous lesion to advanced cancer. A 3-D cancer atlas would allow researchers to develop predictive models of tumor progression and response to treatment.
10. Develop new enabling cancer technologies to characterize tumors and test therapies. These include implantable microdosing drug devices and advanced imaging technologies to study cancers at extremely high resolution.

ESMO 2016 October 7-11 (link to abstract book)



ESMO 2016 | Oncology Conference
ESMO 2016

 Official Journal of the European Society for
Medical Oncology and the Japanese Society of Medical Oncology
Volume 27, 2016 Supplement 6
Abstract Book of the 41st ESMO Congress (ESMO 2016)
Copenhagen, Denmark, 7–11 October 2016


Monday, October 03, 2016

Effects of a (Alberta) Provincial-Wide Implementation of Screening for Distress on Healthcare Professionals' Confidence and Understanding of Person-Centered Care in Oncology



Blogger's Note: 1 gyn cancer patient included


open access
 Effects of a Provincial-Wide Implementation of Screening for Distress on Healthcare Professionals' Confidence and Understanding of Person-Centered Care in Oncology

Background: Although published studies report that screening for distress (SFD) improves the quality of care for patients with cancer, little is known about how SFD impacts healthcare professionals (HCPs).  
Objectives: This quality improvement project examined the impact of implementing the SFD intervention on HCPs' confidence in addressing patient distress and awareness of person-centered care. Patients and Methods: This project involved pre-evaluation and post-evaluation of the impact of implementing SFD. A total of 254 HCPs (cohort 1) were recruited from 17 facilities across the province to complete questionnaires. SFD was then implemented at all cancer care facilities over a 10-month implementation period, after which 157 HCPs (cohort 2) completed post-implementation questionnaires. At regional and community care centers, navigators supported the integration of SFD into routine practice; therefore, the impact of navigators was examined.  
Results: HCPs in cohort 2 reported significantly greater confidence in managing patients' distress and greater awareness about person-centered care relative to HCPs in cohort 1. HCPs at regional and community sites reported greater awareness in person-centeredness before and after the intervention, and reported fewer negative impacts of SFD relative to HCPs at tertiary sites. Caring for single or multiple tumor types was an effect modifier, with effects observed only in the HCPs treating multiple tumors.  
Conclusions: Implementation of SFD was beneficial for HCPs' confidence and awareness of person-centeredness. Factors comprising different models of care, such as having site-based navigators and caring for single or multiple tumors, influenced outcomes.

Crossing the Line (direct to consumer advertising)



JNCCN

NCCN Imaging Appropriate Use Criteria (20 types of cancer + ovarian cancer)



NCCN Imaging Appropriate Use Criteria

NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™)

 NCCN Imaging AUC currently are available for 20 cancer types; the new NCCN Imaging AUC are available for:

  • Esophageal and Esophagogastric Junction Cancers
  • Gastric Cancer
  • Malignant Pleural Mesothelioma
  • Melanoma
  • Ovarian Cancer
  • Penile Cancer
  • Small Cell Lung Cancer
  • Thymomas and Thymic Carcinomas
About NCCN Imaging AUC™
NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™) include information designed to support clinical decision-making around the use of imaging in patients with cancer and are based directly on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). NCCN Imaging AUC™ are available free of charge to registered users of NCCN.org
NCCN Imaging AUC™ include recommendations pertaining to cancer screening, diagnosis, staging, treatment response assessment, follow-up, and surveillance. Additional information includes the indication, imaging modality, and frequency of use, as well as clinical notes related to the specific recommendation. NCCN Imaging AUC™ also document information on disease stage and histology. All imaging procedures recommended in the NCCN Guidelines®, including radiographs, computed tomography (CT) scans, magnetic resonance imaging (MRI), functional nuclear medicine imaging (PET, SPECT) and ultrasound, are included within NCCN Imaging AUC™.
NCCN Imaging AUC™ are accessible through an easy to use web-based user interface. The NCCN Imaging AUC™ include a full complement of imaging AUC in oncology care. NCCN, a CMS-approved Provider Led Entity (PLE), is committed to assuring that the most up-to-date recommendations are available and reviews and updates NCCN Imaging AUC™ on a continual basis to ensure that the recommendations take into account the most current evidence.

Apply for a Research Grant | The Rivkin Center for Ovarian Cancer research



Apply for a Research Grant

 The Rivkin Center has multiple streams of funding to support ovarian cancer research. Please see the following links for current requests for applications, guidelines, and forms.

2016 ESC Position Paper on cancer treatments and cardiovascular toxicity



open access:
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines | European Heart Journal

 Embedded Image
 aWhen used in combination with anthracyclines and cyclophosphambIn patients receiving concurrent anthracyclines

 
1. Introduction
Advances in treatment have led to improved survival of patients with cancer, but have also increased morbidity and mortality due to treatment side effects.1,2 Cardiovascular diseases (CVDs) are one of the most frequent of these side effects, and there is a growing concern that they may lead to premature morbidity and death among cancer survivors.3 This may be the result of cardiotoxicity, which involves direct effects of the cancer treatment on heart function and structure, or may be due to accelerated development of CVD, especially in the presence of traditional cardiovascular risk factors.4
Although the field of cardio-oncology has received increasing attention in recent years, many aspects of both radiation-induced and cancer drug–induced CVD are still to be fully elucidated. Furthermore, the inability to predict the long-term consequences of cancer treatment–associated cardiovascular side effects leads to under- or overdiagnosis of CVD, sometimes resulting in the failure to prevent adverse events and sometimes to inappropriate interruption of a potentially lifesaving cancer treatment.
The complex issue of CVD as a consequence of previous cancer treatment requires the creation of multidisciplinary teams involving specialists in cardiology, oncology and other related fields.....

Abbreviations and acronyms

2-D
two-dimensional
3-D
three-dimensional
5-FU
5-fluorouracil
ACE
angiotensin-converting enzyme
ARB
angiotensin II receptor blocker
ASE
American Society of Echocardiography
BNP
B-type natriuretic peptide
CABG
coronary artery bypass graft
CAD
coronary artery disease
CHA2DS2-VASc
Congestive heart failure or left ventricular dysfunction, Hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female)
CMR
cardiac magnetic resonance
COT
registry Cardiac Oncology Toxicity registry
CT
computed tomography
CTRCD
Cancer Therapeutics–Related Cardiac Dysfunction
CVD
cardiovascular disease
EACVI
European Association of Cardiovascular Imaging
ECG
electrocardiogram / electrocardiographic
ESC
European Society of Cardiology
GLS
global longitudinal strain
GY
gray
HAS-BLED
Hypertension, Abnormal renal/liver function (1 point each), Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly (1 point each)
HDAC
histone deacetylase
HER2
human epidermal growth factor receptor 2
HF
heart failure
LMWH
low molecular weight heparin
LV
left ventricle / left ventricular
LVEF
left ventricular ejection fraction
NA
not available
NOAC
non-vitamin K antagonist oral anticoagulant
NT-proBNP
N-terminal pro-B-type natriuretic peptide
NYHA
New York Heart Association
PAD
peripheral artery disease
PAH
pulmonary arterial hypertension
PCI
percutaneous coronary intervention
RCT
randomized controlled trial
T-DM1
trastuzumab-emtansine
TKI
tyrosine kinase inhibitor
VEGF
vascular endothelial growth factor
VHD
valvular heart disease
VKA
vitamin K antagonist
VTE
venous thromboembolism
WHO
World Health Organization

Glaxo to pay $20 million for bribing doctors in China



pharma news

I Had to Get Cancer to Become a More Empathetic DoctorI Had to Get Cancer to Become a More Empathetic Doctor



abstract: Annals of Internal Medicine

 I am 80 and a retired infectious diseases physician. I have always thought of myself as caring, compassionate, and warm. I thought I knew what patients were feeling, but only now that I have a life-threatening illness do I understand what it's really like to be a patient.

HRT Benefits Premenopausal Women After Ovary Removal - Clinical Oncology News



Clinical Oncology News

 A U.K. study that evaluated the cost-effectiveness of risk-reducing salpingo-oophorectomy (RRSO), the most successful intervention to prevent ovarian cancer, has emphasized the importance of hormone replacement therapy (HRT) in premenopausal women after surgery.
 Original article (abstract): Specifying the ovarian cancer risk threshold of ‘premenopausal risk-reducing salpingo-oophorectomy’ for ovarian cancer prevention: a cost-effectiveness analysis J Med Genet 2016;53:9 591-599

Outcomes included in the analyses were OC, breast cancer (BC) and additional deaths from coronary heart disease. Total costs and effects were estimated in terms of quality-adjusted life-years (QALYs); incidence of OC and BC; as well as incremental cost-effectiveness ratio (ICER).

How Does Surgical Volume Affect Gynecologic Surgery Outcomes?



medscape

 .....We have been aware for some time that patients of higher-volume surgeons have lower perioperative morbidity. However, for gynecologic procedures, it has not been clear whether such an inverse relationship between surgical volume and outcomes is present.
Investigators performed a review and meta-analysis of 14 reports that included almost 750,000 gynecologic surgeries.[1] Eleven of these reports were based in the United States and the remainder were from Holland and Canada. Those who performed surgery once a month or less frequently were considered low-volume surgeons. Hysterectomy and myomectomy procedures were categorized as gynecologic surgeries, endometrial and ovarian cancer procedures as oncology surgeries, and midurethral sling and pelvic reconstructive procedures as urogynecologic surgeries.
Overall, high-volume surgeons tended to operate on patients with more comorbidities. For gynecologic surgeries, low-volume surgeons had higher rates of intraoperative complications such as ureteral, bladder, bowel, and vascular injuries, as well as postoperative morbidity such as wound complications, hemorrhage, ileus, bowel obstruction, and venous thromboembolism. For oncology surgeries, patients of low-volume surgeons had higher perioperative mortality. One report found that among women undergoing surgery for ovarian cancer, 5-year survival was significantly higher with high-volume surgeons. In the urogynecologic category, one study found a higher rate of overall complications among patients of low-volume surgeons. Another noted a higher rate of reoperation for mesh complications following sling procedures performed by low-volume surgeons.
Recently, leaders at three US academic health systems announced a "Take the Volume Pledge" campaign to prevent certain surgeries (none of which are gynecologic) from being performed by low-volume surgeons.[2] This important article suggests that hospitals and particularly payers will increasingly be scrutinizing gynecologic surgeons' volume. Accordingly, gynecologic surgeons would be prudent to assess their own experience level as they plan surgical management of their patients.
Thank you for taking the time to view this video. I'm Andrew Kaunitz.

 References
  1. Mowat A, Maher C, Ballard E. Surgical outcomes for low-volume vs high-volume surgeons in gynecology surgery: a systematic review and meta-analysis. Am J Obstet Gynecol. 2016;215:21-33. Abstract
  2. Urbach DR. Pledging to eliminate low-volume surgery. N Engl J Med. 2015;373:1388-1390. Abstract

Cancer mortality differs among Asian ethnic groups



Medical News Today

Cancer not mainly down to 'bad luck,' finds stem cell study (but....)



Medical News 

In January 2015, a study published in the journal Science suggested that 22 of 31 cancer types - including ovarian, pancreatic, and bone cancers - were down to random "accidental" mutations that arise in normal adult stem cells as they divide.
The new research, however - led by Dr. Ruben van Boxtel of the Department of Genetics at University Medical Center Utrecht in the Netherlands - suggests these "bad luck" mutations do not contribute to cancer development as much as last year's report claims.

Sunday, October 02, 2016

Cancer immunotherapy is moving fast. Here’s what you need to know (media)



The Washington Post

 ......Over the next decade, the growth in the field will be "exponential," predicts Philip Greenberg, head of the immunology program at the Fred Hutchinson Cancer Research Center. "Making something better is enormously different than making something work that doesn't work."
At the same time, researchers remember the past anti-cancer efforts that fizzled after initially showing promise. That explains the consensus sentiment at this week's international immunotherapy conference in New York: Turning science into cures will take years of perseverance against daunting hurdles.
Here's a primer about new treatments and how they work:
What is cancer immunotherapy?.....

Immunotherapy for Ovarian Cancer - Cancer Research Institute



Immunotherapy for Ovarian Cancer 


Cancer Research Institute LogoAbout

IMMUNOTHERAPY FOR OVARIAN CANCER

Current immunotherapies for ovarian cancer fall into six broad categories: monoclonal antibodies; checkpoint inhibitors and immune modulators; therapeutic vaccines; adoptive T cell transfer; oncolytic viruses; and adjuvant immunotherapies. Most of these therapies are still in early-phase testing (phase I and II) for ovarian cancer, but their successful use in other types of cancers suggests that they may ultimately prove useful for ovarian cancer as well.

Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk...



abstract:
Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study

 Long and irregular menstrual cycles, a hallmark of polycystic ovary syndrome (PCOS), have been associated with higher androgen and lower sex hormone binding globulin levels and this altered hormonal environment may increase the risk of specific histologic subtypes of ovarian cancer. We investigated whether menstrual cycle characteristics and self-reported PCOS were associated with ovarian cancer risk among 2041 women with epithelial ovarian cancer and 2100 controls in the New England Case-Control Study (1992-2008). Menstrual cycle irregularity, menstrual cycle length, and PCOS were collected through in-person interview. Unconditional logistic regression models were used to calculate odds ratios (OR) and 95% confidence intervals (95% CIs) for ovarian cancer risk overall, and polytomous logistic regression to evaluate whether risk differed between histologic subtypes. Overall, we observed no elevation in ovarian cancer risk for women who reported periods that were never regular or for those reporting a menstrual cycle length of >35 days with ORs of 0.87 (95% CI=0.69-1.10) and 0.83 (95% CI=0.44-1.54), respectively. We observed no overall association between self-reported PCOS and ovarian cancer (OR=0.97; 95% CI=0.61-1.56). However, we observed significant differences in the association with menstrual cycle irregularity and risk of ovarian cancer subtypes (pheterogeneity=0.03) as well as by BMI and OC use (pinteraction<0.01). Most notable, menstrual cycle irregularity was associated with a decreased risk of high grade serous tumors but an increased risk of serous borderline tumors among women who had never used OCs and those who were overweight. Future research in a large collaborative consortium may help clarify these associations.

HHS Whiteboard on Health Care Data - YouTube (3:13 min) eg. patient access EHR



YouTube

1,338 views
Published on Sep 27, 2016
Learn about our work at HHS to help patients and health care providers unlock their health care information, and use it to stay healthy.
--
U.S. Department of Health and Human Services (HHS)
http://www.hhs.gov

We accept comments in the spirit of our comment policy:
http://www.hhs.gov/web/socialmedia/po...

HHS Privacy Policy
http://www.hhs.gov/Privacy.html
  • Category

  • License

    • Standard YouTube License

Ovarian Cancer and Us (blog): what you are reading today top 5: (so far) - blog/Twitter/FB



feed
 







Ovarian Cancer and Us (blog): what you were reading this week top 10 (blog/Twitter/FB)



feed


























































 




























Ovarian Cancer Canada - selected financials 2014-2016 (per Revenue Canada)



Reporting periods

Quick View
Select Quick View for 2016-03-31 
Select Quick View for2015-03-31
Select Quick View for2014-03-31
Select Quick View for2013-03-31
Select Quick View for2012-03-31
Full View
Select Full View for2016-03-31
Select Full View for2015-03-31
Select Full View for2014-03-31
Select Full View for2013-03-31
Select Full View for2012-03-31
Operations outside Canada
1 country
  • Asia and Oceania - Other



CDC (U.S. 2016) death rates - pancreatic vs breast vs ovarian



Pancreatic = 41,780

Breast = 40,450

Ovarian = 14,240

 

What are the key statistics about ovarian cancer?

The American Cancer Society estimates for ovarian cancer in the United States for 2016 are:
  • About 22,280 women will receive a new diagnosis of ovarian cancer.
  • About 14,240 women will die from ovarian cancer.

How common is pancreatic cancer?

The American Cancer Society’s most recent estimates for pancreatic cancer in the United States for 2016 are:
  • About 53,070 people (27,670 men and 25,400 women) will be diagnosed with pancreatic cancer.
  • About 41,780 people (21,450 men and 20,330 women) will die of pancreatic cancer.
 Current year estimates for breast cancer

The American Cancer Society's estimates for breast cancer in the United States for 2016 are:
  • About 246,660 new cases of invasive breast cancer will be diagnosed in women.
  • About 61,000 new cases of carcinoma in situ (CIS) will be diagnosed (CIS is non-invasive and is the earliest form of breast cancer).
  • About 40,450 women will die from breast cancer.

More deaths from pancreatic cancer than breast cancer in the EU by 2017: Acta Oncologica: Vol 55, No 9-10



abstract

Introduction: Pancreatic cancer currently ranks below female breast cancer in terms of the number of deaths in both males and females in the EU. While breast cancer mortality rates have been declining in many higher income EU countries during recent decades, rates of pancreatic cancer in contrast are either stable or moderately increasing; a comparative analysis of the short-term future rates of both is warranted.
Methods: We extracted the annual number of deaths from cancers of the pancreas and breast by gender together with population at risk in each of 28 countries of the EU for the period 2001–2010. We fitted cancer- and gender-specific time-linear regression models and predicted deaths from pancreatic and breast cancer mortality for the years 2011–2025.
Results: We estimated that by the year 2017 more deaths from pancreatic cancer will occur (91 500 annual deaths) than breast cancer (91 000) in the EU. By 2025, deaths from cancer of the pancreas are predicted to be 25% higher (111 500 and 90 000, respectively). Pancreatic cancer may become the third leading cause of death from cancer in the EU after lung and colorectal cancers.
Conclusion: Although strategies may emerge in the near future that will enhance the prospects of improving the very poor five-year survival from pancreatic cancer, coordinated efforts are necessary to reduce the foreseeable high mortality burden of disease within the EU.

What’s in Your Herbal Pills? Firm Promises DNA Testing for Proof



The New York Times

Lessons in Friendship During Cancer - "bonus friends"



Cure Today

Saturday, October 01, 2016

Where you live shapes your immune system more than your genes



Science news

Active follow-up versus passive linkage with cancer registries for case ascertainment in a cohort (U.S.)



abstract - Cancer Epidemiology

 Background
Ascertaining incident cancers is a critical component of cancer-focused epidemiologic cohorts and of cancer prevention trials. Potential methods: for cancer case ascertainment include active follow-up and passive linkage with state cancer registries. Here we compare the two approaches in a large cancer screening trial.

Methods

The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial enrolled 154,955 subjects at ten U.S. centers and followed them for all-cancer incidence. Cancers were ascertained by an active follow-up process involving annual questionnaires, retrieval of records and medical record abstracting to ascertain and confirm cancers. For a subset of centers, linkage with state cancer registries was also performed. We assessed the agreement of the two methods in ascertaining incident cancers from 1993 to 2009 in 80,083 subjects from six PLCO centers where cancers were ascertained both by active follow-up and through linkages with 14 state registries.

Results

The ratio (times 100) of confirmed cases ascertained by registry linkage compared to active follow-up was 96.4 (95% CI: 95.1–98.2). Of cancers ascertained by either method, 86.6% and 83.5% were identified by active follow-up and by registry linkage, respectively. Of cancers missed by active follow-up, 30% were after subjects were lost to follow-up and 16% were reported but could not be confirmed. Of cancers missed by the registries, 27% were not sent to the state registry of the subject’s current address at the time of linkage.

Conclusion

Linkage with state registries identified a similar number of cancers as active follow-up and can be a cost-effective method to ascertain incident cancers in a large cohort.

Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis (open access)



open access

Friday, September 30, 2016

Extended Adjuvant AIs: Safe and Active, but Not Much Good (breast cancer/high risk)



Clinical Oncology News

The Relevance of Pragmatic Randomized Cancer Trials (note references to ovarian cancer)



Clinical Oncology News

Search of: axitinib | Open Studies - List Results - ClinicalTrials.gov



35 studies found for:    axitinib | Open Studies | Exclude Unknown





Recycling approved drugs for cancer treatment - axitinib



Medical News

Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women- KEEPS trial



Open access:
Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPS–Cognitive and Affective Study

ELITE Trial Supports 'Timing Hypothesis' for Estrogen Therapy (Transcript)



ELITE Trial (Medscape)

CME: Then and Now: Experts Insights on Understanding the WHI's HRT/ERT Trials - updated



Pretest - Then and Now: Experts Insights on Understanding the Women’s Health Initiative Hormone Therapy Trials

(repeat) 25:24 min interview (Narod) Are women undergoing unnecessarily invasive cancer surgeries?



TVO.org

Ovarian Cancer Action - know the signs and symptoms - YouTube



YouTube 2:26 min (2014)